Company: PRTC
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001782999-25-000005
Chunk: 109

Company: PureTech Health plc
Filing Date: 2025-04-30
Form: 20-F
Item: Item 16E
Chunk 109
---
 parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase ordinary shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All ordinary shares repurchased under the Program were then held in treasury.
2.On May 18, 2024, the Board of Directors approved a tender offer to purchase up to an aggregate of $100 million of ordinary shares (including ordinary shares represented by ADSs), subject to shareholder approval, certain limitations and legal requirements (“Tender Offer”). The Tender Offer commenced on May 20, 2024 and expired at 5:00 P.M., New York City time, on June 18, 2024 with respect to ADSs and 1:00 p.m., London time, on June 20, 2024 with respect to ordinary shares. Jefferies implemented the Tender Offer by acquiring, as principal, the successfully tendered ordinary share (including ordinary shares represented by ADSs) at a fixed price of 250 pence per ordinary share (equivalent to £25.00 per ADS) (the “Tender Price”), with such purchases being market purchases. Immediately following completion of the Tender Offer, Jefferies exercised its right to sell such ordinary share (including ordinary shares represented by ADSs) to the Company, at the Tender Price. On June 24, 2024, a total of 31,540,670 ordinary shares (including ordinary shares represented by ADSs) were repurchased by the Company in connection with the Tender Offer, representing approximately 12% of the issued ordinary share capital of the Company. All ordinary shares repurchased in connection with the Tender Offer have been cancelled.